Clinical trials
Prostatic Cancer clinical trials
Below are recruiting prostatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,219 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07071207Recruiting
Text reminders after prostate surgery
This trial tests if text message reminders help men recover urinary control after prostate surgery. If you are planning prostate surgery and can use a mobile phone for texts, you may be able to join.
Rochester, New YorkAges 18 years+ - NCT06302595Recruiting
MRI-guided prostate biopsy for cancer diagnosis
This trial uses MRI to guide a biopsy of the prostate, aiming to better detect cancer in men with abnormal PSA levels, a lump, or a suspicious MRI finding.
Boston, MassachusettsAges 30 years+ - NCT04197414Recruiting
Urology DNA registry to personalize cancer care
This study builds a urology cancer “DNA registry” by analyzing circulating tumor DNA found in the blood. Your information and permission help researchers better personalize treatment for cancers like prostate, kidney, bladder, and ureter cancer.
SeoulAges 20 years+ - NCT04625556Recruiting
Urology cancer registry study using body microbiome data
This study builds a patient registry for prostate, kidney, bladder, and ureter cancers by analyzing your body’s microbiome (the microbes living in/ on the body). It may help doctors personalize care in the future, and your participation mainly involves allowing your medical and related information to be used for research.
SeoulAges 20 years+ - NCT02705846Recruiting
Study tracks outcomes in men with inherited prostate cancer risks
This study looks at how prostate cancer diagnoses and treatments turn out over time. It compares men who carry rare inherited gene changes that raise prostate cancer risk with men who do not, to better understand which treatments and outcomes may differ.
Sutton, SurreyAges 18 years+ - NCT04188535Recruiting
MRI scans during radiation treatment
This study does repeated MRI (detailed brain/body imaging) while you receive radiation therapy. It aims to see how these serial scans relate to treatment and outcomes, which could help improve care planning for different cancers.
Boston, MassachusettsAges 18 years+ - NCT07660211RecruitingPhase 1
Radioactive treatment for advanced prostate cancer
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06549465RecruitingPhase 2
Ac-225 rosopatamab for PSMA-positive castration-resistant prostate cancer
This trial tests a radioactive drug (Ac-225 rosopatamab tetraxetan) that targets a protein called PSMA on prostate cancer cells. It is for patients whose cancer has stopped responding to hormone therapy and has spread to other parts of the body.
San Diego, CaliforniaAges 18 years+ - NCT04916613RecruitingPhase 3
ADT plus darolutamide for vulnerable newly metastatic prostate cancer
This trial studies whether adding darolutamide to standard hormone therapy (ADT) helps men with newly diagnosed metastatic prostate cancer who are physically vulnerable. It aims to control the cancer better while checking safety and how well treatment is tolerated in this group.
CharleroiAges 18 years+ - NCT06001255RecruitingPhase 2
Testing HS-20093 for advanced prostate and other solid cancers
This trial is testing a new drug called HS-20093 for people with advanced prostate cancer or other solid tumors that have spread and stopped responding to standard treatments. The drug targets a protein on cancer cells to try to stop cancer growth.
BeijingAges 18 years+ - NCT07311694RecruitingPhase 3
Comparing a new treatment with standard drugs for advanced prostate cancer
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT04271579Recruiting
Surgery for early prostate cancer spread seen on PSMA PET
This trial studies whether operating on a small, one-sided (unilateral) area of prostate cancer spread in the pelvic lymph nodes—found on a PSMA PET scan—can help control recurrence. It’s meant for people whose PSA is still low and whose spread appears limited on the scan.
HamburgAges 18–75 - NCT06282588RecruitingPhase 2/Phase 3
Advanced imaging-guided treatment for high-risk prostate cancer
This trial uses a special PET scan (PSMA PET/CT) and a genetic test (Decipher) to decide the best treatment for high-risk prostate cancer that hasn't spread outside the pelvis. You'll receive standard radiation and hormone therapy, possibly with an extra drug (darolutamide).
Wilrijk, AntwerpAges 18 years+ - NCT06594926RecruitingPhase 2
Bipolar androgen therapy for prostate cancer without metastases
This trial tests a treatment called bipolar androgen therapy for men with prostate cancer that has not spread to other parts of the body and is still growing despite taking darolutamide. The goal is to see if this therapy can help control the cancer.
Garran, Australian Capital TerritoryAges 18 years+ - NCT06766526Recruiting
Online support for emotional adjustment after prostate cancer
This trial tests an online support program to help men cope with emotional distress after prostate cancer. You participate from home using a computer or smartphone.
LinköpingAges 18 years+ - NCT07209878RecruitingPhase 2/Phase 3
PET scan vs. MRI for prostate cancer diagnosis
This trial compares two types of imaging scans (a PSMA PET scan and an MRI) to see which is better at finding prostate cancer. You may be able to join if you are scheduled for prostate removal surgery and haven't started cancer treatment yet.
Fuzhou, FujianAges 18–80 - NCT07336446RecruitingPhase 1/Phase 2
Testing AZD9750 for metastatic prostate cancer with or without other drugs
This trial is for men with metastatic prostate cancer that has gotten worse despite treatment. It tests a new drug called AZD9750, given alone or with other cancer drugs, to see if it is safe and works well.
Duarte, CaliforniaAges 18 years+ - NCT07605936Recruiting
Understanding Frailty in Older Men With Prostate Cancer
This study looks at how frailty (physical weakness and loss of strength) affects older men who have been diagnosed with prostate cancer. Researchers want to understand which men are at higher risk and how this might guide better treatment decisions.
Limerick, MunsterAges 65 years+ - NCT04969315RecruitingPhase 1/Phase 2
Drug TT-10 and TT-4 for advanced solid tumors
This early-phase trial tests two investigational drugs—TT-10 and TT-4—alone and together in people with advanced solid cancers. The study is designed to find safe doses and see if the treatment can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT04212715RecruitingPhase 2
Extra radiation boost for high-risk prostate cancer
This Phase 2 study tests a treatment plan that uses standard focused radiation to the prostate, plus an extra “boost” delivered inside the prostate. It may help improve control of high-risk prostate cancer, especially by aiming radiation more precisely.
RiyadhAges 18–99 - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06461819RecruitingPhase 2
Higher radiation dose for low-to-intermediate prostate cancer
This trial tests if giving a higher dose of radiation in fewer sessions, while using SpaceOAR to protect the rectum, is safe for men with low-to-intermediate risk prostate cancer that hasn't spread.
SeoulAges 20 years+ - NCT07690917Recruiting
New PET scanner study for people with cancer
This trial tests a new PET scanner that may help doctors see where cancer is in your body more clearly. It is for adults with lung, prostate, or head and neck cancer who are already scheduled for a PET-CT scan at Memorial Sloan Kettering.
Basking Ridge, New JerseyAges 18 years+
Hear when a new Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatic cancer?
- Yes. Clin2 currently lists 1,219 recruiting prostatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.